ACM
AVXL icon

AlphaCrest Capital Management’s Anavex Life Sciences AVXL Stock Holding History

AlphaCrest Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28,994
Closed -$299K – 110
2022
Q3 		$299K Sell
28,994
-16,732
-37% -$177K 0.02% 1139
2022
Q2 		$458K Buy
45,726
+4,409
+11% +$41.8K 0.02% 984
2022
Q1 		$509K Buy
41,317
+28,326
+218% +$348K 0.03% 887
2021
Q4 		$225K Sell
12,991
-1,409
-10% -$26.8K 0.01% 1313
2021
Q3 		$258K Buy
+14,400
New +$287K 0.01% 1150

Other funds holding AVXL

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

AlphaCrest Capital Management's AVXL Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Anavex Life Sciences (AVXL) in Q4 2022, closing a stake of 28,994 shares — an estimated $299K sold.

AlphaCrest Capital Management first reported a position in AVXL in Q3 2021 and held it in 5 quarters. The position peaked at $509K in Q1 2022. 139 funds tracked by Wall St. Rank hold AVXL as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Anavex Life Sciences position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 28,994 Anavex Life Sciences shares in Q4 2022, an estimated $299K.
  • AlphaCrest Capital Management first reported a position in Anavex Life Sciences in Q3 2021 and held it in 5 quarters.
  • AlphaCrest Capital Management's Anavex Life Sciences position peaked at $509K in Q1 2022.
  • 139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.